increas
indic
hsct
past
decad
improv
surviv
concern
grown
advers
effect
hsct
pc
infecti
caus
recent
report
occur
adult
paediatr
hsct
recipi
usual
relat
poor
variou
diagnost
test
util
identifi
aetiolog
pi
target
therapi
depend
condit
recipi
howev
controversi
exist
regard
whether
clear
diagnosi
lead
better
pc
eventu
caus
respiratori
failur
mechan
ventil
singl
multipl
organ
dysfunct
identifi
predispos
factor
relat
given
need
mechan
ventil
critic
care
transplant
associ
poor
condit
contribut
deterior
patient
pc
investig
howev
previou
studi
report
factor
relat
pc
develop
focus
prevent
strategi
thu
studi
current
exist
regard
earli
predictor
respiratori
failur
death
associ
pc
therefor
aim
studi
evalu
abil
diagnost
final
diagnos
treatment
modif
medic
condit
time
pc
initi
predict
mortal
hsct
recipi
children
januari
decemb
paediatr
patient
underw
hsct
hospit
initi
exclud
recipi
loss
graft
recipi
transfer
anoth
hospit
due
progress
underli
diseas
immedi
follow
stem
cell
infus
sixteen
patient
underw
second
hsct
plan
transplant
studi
period
case
consid
second
hsct
among
evalu
paediatr
patient
pc
investig
relaps
death
decemb
whichev
came
first
total
pi
episod
patient
retrospect
identifi
median
period
month
iqr
final
includ
present
studi
studi
accord
helsinki
declar
institut
review
board
approv
obtain
studi
data
collect
regard
gener
characterist
includ
factor
clinic
find
outcom
pc
episod
gener
characterist
assess
includ
age
sex
underli
diseas
previou
lung
problem
number
type
hsct
stem
cell
sourc
engraft
day
human
leucocyt
antigen
compat
allograft
underli
diseas
categor
leukaemialymphoma
solid
tumour
diseas
includ
primari
immunodefici
aplast
anaemia
osteopetrosi
previou
lung
problem
identifi
patient
activ
lung
diseas
time
hsct
infus
neutrophil
engraft
day
defin
consecut
day
absolut
neutrophil
count
greater
equal
cellsl
pc
defin
new
develop
pi
chest
radiographi
simultan
respiratori
symptom
requir
admiss
evalu
treatment
respiratori
symptom
includ
cough
sputum
dyspnoea
chest
pain
blood
ting
sputum
cyanosi
pc
episod
time
diagnosi
transplant
diagnost
procedur
appli
time
bal
lb
sinc
pi
appear
relev
medic
condit
investig
addit
chang
empir
treatment
attribut
result
diagnost
test
record
evalu
medic
condit
time
pi
initi
consid
follow
presenc
engraft
syndrom
acut
gvhd
chronic
gvhd
vod
cmv
infect
medic
administr
organ
dysfunct
identifi
use
specif
pediatr
critic
care
medicin
criteria
publish
criteria
organ
dysfunct
cardiovascular
neurolog
haematolog
renal
gastrointestin
hepat
system
evalu
data
indic
sever
condit
within
hour
pi
appear
use
respiratori
dysfunct
exclud
criteria
arteri
blood
ga
frequent
measur
children
mild
respiratori
distress
acut
chronic
gvhd
assess
describ
cmv
infect
defin
need
cur
induct
therapi
ganciclovir
treatment
start
therapi
ganciclovir
cmv
antigenemia
assay
result
show
polymorphonuclear
leucocyt
induct
therapi
start
result
show
antigen
express
polymorphonuclear
leucocyt
drug
alreadi
administ
note
follow
antibiot
antifung
agent
intraven
inject
inotrop
vasopressor
immunosuppress
includ
tacrolimu
cyclosporin
mycophenol
mofetil
steroid
prophylaxi
treatment
complic
accord
analysi
accompani
medic
condit
earli
predictor
mortal
defin
statist
signific
comorbid
occur
pc
within
hour
pi
initi
outcom
episod
consid
term
number
admiss
picu
unexpect
event
cpr
unplan
transfer
picu
surviv
hospit
discharg
caus
death
clarifi
relat
pi
includ
patient
die
result
pc
reason
two
patient
die
classifi
survivor
group
die
due
recurr
underli
diseas
pi
evalu
use
andor
invas
test
includ
blood
cultur
sputum
examin
serolog
test
chest
ct
scan
echocardiographi
pulmonari
function
test
sputum
collect
expector
use
nasopharyng
aspir
swab
transtrach
aspir
patient
alreadi
intub
sputum
gram
stain
cultur
bacteria
viru
fungi
subject
pcr
virus
mycoplasma
pneumonia
addit
bacillu
stain
sputum
cultur
perform
high
suspicion
mycobacterium
tuberculosi
infect
exist
serolog
test
cmv
antigen
test
viral
load
aspergillu
antigen
test
mycoplasma
antibodi
assess
invas
test
bal
lb
arrang
base
joint
discuss
oncologist
pulmonologist
intensivist
radiologist
bal
perform
paediatr
pulmonologist
use
flexibl
bronchoscop
steril
normal
salin
instil
aliquot
ml
suction
sent
patholog
microbiolog
evalu
vat
lb
perform
paediatr
thorac
surgeon
lb
perform
paediatr
radiologist
biopsi
bal
sampl
screen
infecti
pathogen
gram
gomori
methenamin
silver
stain
viral
immunostain
sampl
also
process
bacteria
virus
fungi
cultur
pcr
mycobacterium
cmv
respiratori
viru
includ
respiratori
syncyti
viru
metapneumoviru
parainfluenza
influenza
rhinoviru
adenoviru
addit
perform
use
bal
fluid
immunofluoresc
assay
pcr
detect
pneumocysti
jiroveci
also
util
diagnos
base
clinic
radiolog
microbiolog
patholog
find
thoroughli
review
two
author
yhc
jdp
diagnos
classifi
definit
probabl
follow
definit
bacteri
pneumonia
defin
bal
fluid
contain
identifi
pathogen
amount
cfuml
definit
viral
pneumonia
defin
detect
viru
histopatholog
probabl
viral
pneumonia
defin
discoveri
viru
pcr
cultur
bal
fluid
sputum
collect
patient
clinic
featur
consist
viral
pneumonia
posit
test
cmv
antigenemia
plasma
pcr
respiratori
specimen
alon
regard
cmv
fungal
pneumonia
establish
base
definit
consensu
european
organ
research
treatment
cancerinvas
fungal
infect
cooper
definit
diagnosi
p
jiroveci
pneumonia
made
identif
p
jiroveci
bal
lung
tissu
probabl
diagnosi
made
expector
aspir
tuberculosi
diagnos
posit
result
bacillu
stain
cultur
respiratori
pc
follow
diagnos
confirm
ip
pulmonari
oedema
andor
pleural
effus
perd
lung
gvhd
acut
lung
injuri
ild
ip
defin
diffus
alveolar
damag
absenc
identifi
infecti
aetiolog
histolog
ild
defin
similar
manner
ip
character
differ
injuri
site
clinic
featur
accord
recent
perd
consid
presenc
fever
evid
pulmonari
injuri
form
hypoxia
andor
infiltr
chest
radiograph
absenc
clinic
cardiac
diagnos
perd
symptom
andor
radiograph
find
occur
within
day
neutrophil
lung
gvhd
diagnos
primarili
presenc
obstruct
pulmonari
dysfunct
base
pulmonari
function
test
accompani
chest
ct
find
area
show
patchi
infiltr
bronchial
dilat
increas
acut
lung
injuri
identifi
whenev
patient
develop
hypoxem
respiratori
insuffici
shortli
transfus
blood
product
accord
outlin
diagnost
pulmonari
oedema
andor
pleural
effus
defin
presenc
characterist
infiltr
fluid
within
pleural
space
neg
cultur
benefici
respons
diuresi
without
cardiac
dysfunct
exclud
lung
statist
analys
perform
use
spss
softwar
version
spss
inc
ibm
armonk
ny
usa
qualit
variabl
describ
number
continu
variabl
report
mean
median
iqr
gener
characterist
compar
survivor
via
test
fisher
exact
test
categor
data
via
continu
data
logist
regress
perform
identifi
variabl
significantli
associ
poor
outcom
pi
episod
assess
estim
odd
ratio
confid
interv
ci
variabl
show
signific
univari
result
p
includ
multivari
logist
regress
multivari
model
construct
forward
stepwis
method
use
threshold
remov
addit
model
surviv
estim
use
method
differ
assess
use
test
gener
characterist
recipi
male
femal
one
pi
episod
follow
hsct
summar
tabl
median
age
year
iqr
half
patient
leukaemia
lymphoma
recipi
lung
problem
prior
hsct
includ
infecti
diseas
n
diseas
n
cancer
n
patient
undergon
one
hsct
receiv
two
hsct
major
hsct
procedur
allogen
common
stem
cell
sourc
allogen
transplant
origin
peripher
blood
median
number
day
neutrophil
engraft
day
iqr
transplant
addit
recipi
two
pi
episod
median
month
iqr
statist
signific
differ
gener
characterist
survivor
except
length
period
total
episod
lung
infiltr
investig
recipi
period
among
diagnost
pi
evalu
pcr
viru
detect
collect
sputum
commonli
conduct
test
episod
blood
cultur
serum
aspergillu
antigen
test
next
commonli
use
test
episod
episod
chest
ct
perform
pi
first
suspect
episod
iqr
test
cmv
antigenemia
viral
load
mycoplasma
antibodi
commonli
check
episod
episod
howev
sputum
examin
bacteria
pneumocysti
jiroveci
conduct
episod
episod
bal
perform
episod
median
time
day
iqr
pi
visibl
lb
conduct
episod
median
time
day
iqr
addit
episod
evalu
bal
lb
invas
test
prolong
air
leakag
develop
one
patient
undergon
vat
biopsi
howev
case
death
use
test
specif
aetiolog
discov
almost
half
pi
episod
episod
figur
among
two
episod
includ
addit
invas
test
show
use
inform
howev
episod
without
pathogen
discov
test
given
aetiolog
diagnosi
ad
bal
andor
lb
result
diagnost
yield
p
final
vigor
diagnost
investig
infecti
caus
diagnos
episod
caus
diagnos
episod
howev
pc
identifi
episod
tabl
infecti
pc
viral
pneumonia
commonli
identifi
aetiolog
episod
one
three
patient
parainfluenza
viral
infect
experienc
time
among
pc
pulmonari
oedema
andor
pleural
effus
without
heart
dysfunct
lung
gvhd
found
episod
studi
patient
diagnos
cryptogen
organ
pneumonia
bronchiol
obliteran
syndrom
diffus
alveolar
haemorrhag
diagnost
among
complic
present
begin
pi
vod
higher
incid
group
compar
survivor
group
vs
p
tabl
addit
among
medic
administ
intraven
antibiot
cmv
treatment
intraven
antifung
agent
usag
higher
mortal
group
compar
survivor
group
p
number
dysfunct
initi
pi
higher
group
compar
survivor
group
vs
p
term
organ
dysfunct
time
pi
haematolog
hepat
dysfunct
specif
relat
mortal
repres
haematolog
dysfunct
absolut
neutrophil
count
level
platelet
count
lower
group
compar
survivor
group
vs
p
vs
p
respect
addit
platelet
level
lower
episod
mod
compar
episod
without
mod
median
vs
p
control
factor
multivari
analysi
hepat
dysfunct
ci
p
neutropaenia
ci
p
signific
independ
risk
factor
mortal
tabl
neutropaenia
significantli
associ
poor
outcom
among
infecti
caus
among
caus
p
vs
p
figur
show
overal
surviv
rate
patient
without
either
haematolog
hepat
dysfunct
patient
one
dysfunct
patient
vs
vs
p
contrast
aetiolog
confirm
diagnosi
invas
treatment
modif
base
evalu
show
signific
effect
prognosi
model
predict
mortal
well
calibr
test
patient
group
requir
admiss
picu
compar
patient
survivor
group
picu
readmiss
within
day
discharg
also
frequent
observ
group
vs
p
howev
length
period
pi
identif
picu
admiss
significantli
differ
group
retrospect
studi
pi
caus
respiratori
symptom
requir
admiss
paediatr
hsct
recipi
pc
common
occur
recipi
patient
pc
high
mortal
rate
diagnost
aetiolog
could
identifi
episod
invas
test
significantli
improv
diagnost
yield
extens
investig
comorbid
hepat
dysfunct
neutropaenia
within
hour
pc
detect
associ
mortal
regardless
aetiolog
contrast
final
definit
probabl
diagnosi
associ
treatment
modif
associ
outcom
identifi
infecti
pc
respiratori
specimen
typic
inspect
first
expector
sputum
older
children
adolesc
may
use
howev
sampl
nasopharynx
throat
predict
valu
bacteri
studi
gram
stain
cultur
sputum
conduct
episod
viral
studi
conduct
episod
differenti
infecti
aetiolog
indirect
test
addit
perform
serolog
radiolog
evalu
episod
recent
sever
author
emphas
import
ct
diagnosi
pc
hsct
howev
specifi
pc
type
basi
ct
scan
alon
difficult
specif
ct
find
exist
indic
treatment
therefor
precis
distinguish
aetiolog
pc
invas
bal
lb
inevit
previou
studi
bal
perform
adult
recipi
paediatr
hsct
recipi
diagnost
lb
also
yield
specif
diagnosi
lung
especi
pc
overal
diagnost
yield
invas
test
studi
similar
increas
group
neg
result
test
howev
major
episod
diagnos
use
test
bal
lb
perform
total
episod
respect
nevertheless
mortal
rate
lower
present
studi
compar
previou
report
paediatr
manag
pc
critic
depend
possibl
presumpt
diagnosi
clinician
expect
identif
specif
aetiolog
would
allow
therapi
remov
chang
ad
would
lead
surviv
consist
previou
found
modif
treatment
base
examin
result
perform
episod
influenc
outcom
contrast
yoo
et
report
affirm
effect
therapeut
modif
follow
procedur
diffus
pi
caus
respiratori
failur
cancer
patient
howev
studi
may
gener
hsct
patient
limit
special
icu
critic
ill
cancer
patient
furthermor
physician
decid
treatment
base
aetiolog
diagnos
also
respons
empir
treatment
clinic
experi
thu
difficult
find
direct
effect
aetiolog
diagnosi
treatment
modif
outcom
without
consider
medic
condit
howev
previous
mention
studi
pc
analys
comorbid
occur
major
recipi
follow
transplant
may
affect
treatment
choic
outcom
studi
extens
investig
predictor
outcom
inclus
comorbid
well
aetiolog
diagnosi
treatment
modif
although
studi
find
relationship
treatment
modif
outcom
target
therapi
accord
evalu
result
still
recommend
earli
antibiot
may
lead
posit
effect
includ
lower
level
multidrug
resist
bacteria
medic
toxic
organ
dysfunct
frequent
complic
hsct
whether
organ
dysfunct
result
condit
chemotherapi
insult
inflammatori
cytokin
tumour
necrosi
suggest
import
common
pathway
lead
organ
damag
may
toxic
effect
inflammatori
cytokin
vascular
endothelium
lead
state
high
mortal
rate
also
known
occur
result
vascular
endotheli
studi
one
case
viral
pneumonia
coexist
die
mod
among
sever
organ
pulmonari
hepat
central
nervou
system
dysfunct
shown
similar
find
laboratori
test
low
anticoagul
protein
c
antithrombin
iii
clinic
outcom
subsequ
organ
dysfunct
multivari
analysi
organ
dysfunct
begin
pi
found
signific
prognost
factor
patient
pc
follow
hsct
recipi
pi
also
suffer
hepat
dysfunct
frequent
poor
outcom
half
patient
hepat
dysfunct
vod
although
number
patient
small
evalu
outcom
accord
caus
hepat
dysfunct
could
presum
vod
common
caus
liver
dysfunct
might
relat
mortal
patient
pc
addit
whatev
caus
hepat
dysfunct
earli
stage
respiratori
distress
rather
advanc
stage
may
aggrav
respiratori
failur
organ
dysfunct
lead
poor
outcom
gordon
et
report
frequent
platelet
transfus
owe
consumpt
thrombocytopaenia
could
earli
marker
subsequ
organ
dysfunct
present
studi
platelet
level
lower
episod
mod
compar
episod
without
mod
howev
thrombocytopaenia
relat
final
mortal
instead
neutropaenia
earli
prognost
factor
mortal
unexpect
neutropaenia
hsct
result
sever
caus
includ
infect
gvhd
myelosuppress
neutropaenia
graft
neutropen
recipi
expos
risk
opportunist
infect
difficult
overcom
increas
mortal
divid
patient
two
group
aetiolog
neutropaenia
significantli
associ
poor
outcom
among
infecti
caus
among
caus
similar
previou
studi
report
relationship
organ
dysfunct
mortal
howev
present
studi
focus
recipi
pi
earli
predictor
mortal
rather
recipi
hsct
alreadi
critic
ill
patient
organ
dysfunct
worsen
patient
could
transfer
picu
extracorpor
organ
support
among
recipi
pi
episod
requir
picu
admiss
surviv
interestingli
differ
day
diagnosi
picu
admiss
surviv
may
assum
simpl
organ
support
care
earli
transfer
picu
enough
inhibit
progress
mod
mortal
howev
establish
therapi
organ
dysfunct
yet
exist
although
molecular
target
therapi
therefor
studi
organ
dysfunct
treatment
need
improv
outcom
present
studi
sever
limit
first
studi
conduct
singl
centr
may
limit
generaliz
find
centr
close
discuss
among
experienc
oncologist
pulmonologist
intensivist
possibl
second
due
studi
retrospect
natur
select
bia
may
influenc
result
third
patient
group
small
draw
power
conclus
howev
present
studi
add
literatur
focus
import
comorbid
organ
dysfunct
often
neglect
studi
focus
diagnos
addit
adjust
multivari
analysi
serv
minim
potenti
select
bia
final
lack
result
pulmonari
function
test
hsct
limit
studi
howev
recipi
children
younger
year
old
lung
function
test
could
perform
routin
therefor
could
use
rel
factor
pc
conclus
hepat
dysfunct
neutropaenia
time
pi
initi
ascertain
independ
earli
predictor
mortal
although
addit
invas
diagnost
test
led
higher
diagnost
yield
aetiolog
diagnos
associ
treatment
modif
significantli
affect
mortal
howev
observ
need
evalu
multicentr
prospect
studi
author
declar
conflict
interest
yu
hyeon
choi
particip
studi
design
data
collect
statist
analysi
data
interpret
draft
articl
approv
articl
hyung
joo
jeong
hong
yul
sun
kim
eui
jun
lee
particip
studi
design
critic
revis
articl
approv
articl
bongjin
lee
june
dong
park
particip
data
interpret
draft
articl
critic
revis
articl
approv
articl
hyoung
jin
kang
hee
young
shin
particip
data
interpret
critic
revis
